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Introduction
Given limited health care resources and rising expenditures on pharmaceuticals, policy makers are increasingly confronted with the challenging task to improve patient outcomes and reimburse new pharmaceutical interventions [1] . In several countries, including England and Wales, Scotland, The Netherlands, Belgium, Canada, Australia and Sweden, health technology assessment (HTA) bodies have been set up to advise on whether health care interventions should be recommended for public reimbursement [2] [3] [4] . Most HTA bodies consider evidence not only on clinical effectiveness and safety but also on various other factors such as cost-effectiveness and budgetary impact. With more and more national health authorities requesting health economic evaluation for their reimbursement decisions, the significance of economic factors in the advisory or decision-making process has increased.
The importance of the individual components of evidence, e.g. clinical outcomes, disease characteristics, health economic outcomes, which are submitted to local health authorities as part of a reimbursement dossier, however, is generally not described. There is an exception for the National Institute for Health and Care Excellence (NICE) in England and Wales which uses the incremental cost-effectiveness ratio (ICER) threshold of £20,000-£30,000 per qualityadjusted life years (QALY) gained. Yet, NICE appraisals suggest that various factors are also taken into account and a drug can be positively assessed even if the ICER exceeds that threshold. More precisely, as the ICER of an intervention increases in the range of £20,000 to £30,000 per QALY gained, the NICE Committee's judgement about the acceptability of the technology as an effective use of NHS resources will specifically take account of other factors, such as the degree of certainty around ICER, innovative nature of the technology, inadequately captured quality of life benefits and potential "life-extensive" nature of the treatment under assessment [5] . Nevertheless, most countries have not set a formal costeffectiveness threshold for reimbursement; therefore, it is not clear how the economic results relate to other factors in the decision or advisory process.
A number of quantitative studies have been previously conducted to investigate what factors are influential and how impactful these factors are on reimbursement decisions in specific countries, including England and Wales [6] [7] [8] [9] [10] , the Netherlands [11] , and Australia [12, 13] . To our knowledge, no study has been conducted for the Scottish Medicines Consortium (SMC).
Within the National Health Service for Scotland (NHS Scotland), 14 geographically-based local NHS Boards and a number of National Special Health Boards are responsible for the provision of health care [14] . The SMC, a consortium of NHS Scotland, was established to benefit patients by providing NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) with a single source of advice about the value of each new medicine and the patients for whom it would be most beneficial [14, 15] . In particular, the SMC advises NHS Scotland whether a newly licensed drug should be reimbursed based on the value for money it represents to NHS Scotland. The SMC provides a central reimbursement recommendation as soon as possible after the launch of the product, which is based on the clinical and economic evidence provided by the manufacturer [15, 16] . The advisory process involves the assessment of both clinical and economic evidence as submitted by the manufacturer by lead clinicians, pharmacists and health economists together with representatives of health boards, the pharmaceutical industry and patient associations [15, 16] . The SMC can positively assess and accept a drug for either routine or restricted use, or alternatively, it can suggest rejection of public funding of the medicine [16] . On completion of the SMC assessment process, its advice for NHS Scotland is published and the final formulary inclusion decision is made by the local Health Boards using this advice. It is important to note that NHS boards will consider all SMC accepted advice as a matter of course but can still decide not to include such medicines on their own local formulary i.e. where the medicine does not represent sufficient added benefit to other medicines already on the formulary for the same indication [15] . Detailed information is available on the organization's website: (www.scottishmedicinesconsortium.com) [15] . Arguably, Scotland is often one of the first European countries where manufacturers file a submission dossier requesting public reimbursement for their product. Manufacturers submit their evidence to the SMC before they submit to the relevant HTA body of England & Wales, the National Institute for Health and Care Excellence (NICE) [14, 17] . It seems that the SMC's assessment of evidence approach is closer to that used elsewhere in Europe and their activities are to a large extent complementary to the ones of NICE [14, 18] . The SMC advisory process is transparent in the sense that all decisions and argumentations are published on the SMC's website since 2002 [15] . Hence, feedback of the SMC on a submission might have implications on decisions of other health authorities and impact the product's pricing in Europe on the grounds of the reference pricing system [19] .
The purpose of the current study was to investigate the weight that the different pieces of evidence, submitted to the SMC for reimbursement assessment, have on the final recommendation decision by the SMC.
Methods
A comprehensive database was created including information from all drug appraisals performed by the SMC between January 2006 and July 2013. They year of 2006 was chosen as the starting point for the SMC data collection for this analysis as this year was considered to be the one where the SMC's role was strengthened and evolved into the one that it currently has [20] . The SMC publishes the reimbursement recommendation itself together with wideranging details on the submission in a standardized format that is accessible to the general public [15] . Information from 'full submissions' (i.e. submissions for the first time) as well as resubmissions were included in the database. Appraisals that were labelled as 'abbreviated submission' or "IRP guidance (Independent Review Panel)" were not considered for this research because they provided limited information on the submitted evidence.
From each appraisal, numerous variables were extracted. These included the opinion of the SMC (a product being accepted for routine or for restricted use was treated as one category) and several factors that were grouped into five main classes: clinical evidence, therapeutic indication-related information, disease characteristics, health economic evidence, and other relevant information. Altogether, the dataset included 20 variables that were thought to potentially influence the recommendation of the SMC. Table 1 presents these variables together with their definitions and possible sets of values.
The extent to which the submitted evidence influences the final recommendation of the SMC was assessed by odds ratios (OR) estimated from binomial logistic regression analyses. The STATA software was used [22] . Analyses took place in two phases; in the first phase, univariate logistic regression models were set up to examine the relationship between each individual independent variable (explanatory variables) and the decision of the SMC (dependent variable), defined as 'to accept' or 'not to recommend' a product for use within NHS Scotland. In the second phase, a multivariate logistic regression analysis was undertaken to assess how the presence of multiple factors influences the recommendation of the SMC. The explanatory variables that indicated a statistically significant relationship with the dependent variable in the univariate analyses (i.e. P value ≤0.05) were included in the multivariate model. If for a multinomial explanatory variable at least one category was significantly associated with the outcome, then the whole multinomial variable was considered for the multivariate analysis. Missing information led to the exclusion of an observation from the regression analyses.
Variable selection in the multivariate logistic regression model was performed using a backward elimination procedure [23] . Specifically, the backward elimination procedure started with all considered variables (i.e. variables with P value < 0.05 in the univariate analysis), tested the deletion of each variable for model improvement (exit criterion was P value > 0.05), and repeated this process until no further improvement was possible. The backward elimination algorithm was chosen for this study because it is a commonly used and well accepted method for variable selection, and because it is less adversely affected by the correlations among explanatory variables than other methods (e.g. forward selection, stepwise regression methods) [23] . The predictive power of the multivariate model was assessed by the area under the receiver operating characteristic (ROC) curve.
For the base case analysis, resubmissions were treated as original submissions. One could argue, however, that the result of a resubmission was not independent from that of the original submission, as at the resubmission the manufacturer could address the critique expressed by the SMC during the first assessment and could eventually increase the chance of a positive recommendation. If this is true, depending on the strength of this correlation and the number of resubmissions, the standard errors of the analyses may be not correct even though parameter estimates would be still unbiased. To acknowledge this potential limitation, a sensitivity analysis was conducted excluding the subset of resubmissions and its impact on the standard error of the parameter estimates was observed. If more than one trial was reported, the one given as the pivotal trial was extracted and used. An active-controlled trial was preferred over a placebo-controlled study in case more studies were reported and in case none of them was marked as the pivotal one. If more than one active-controlled trial was reported, the one used in the pharmacoeconomic analysis section of the SMC document was chosen to be extracted. 
Disease characteristics
Orphan indication
No orphan indication Orphan indication was given to products that were recognized by the European Medicines Agency as orphandesignated medicines to treat an orphan disease. An orphan (rare) disease affects a small percentage of the population (about 5 in 10,000 people [20] ). If a range of base-case ICERs was reported because multiple analyses were conducted for different drug comparators, the ICER of an analysis based on an active-controlled trial was preferred to be extracted over the ICER of an analysis based on a placebo-controlled trial. If more than one ICER was reported for the same analysis/comparator as the submission dossier may cover more than one population, we conservatively extracted the higher reported one.
Budget impact at year 5
Estimated net budget impact at year 5 is over £500,000 D ¼ 2; Estimated net budget impact at year 5 is below £500,000 The manufacturer is requested to estimate and submit a budgetary impact of introducing a new product into the current treatment setting assuming the product of interest is on the market for 5 y.
Budget impact overestimation/ underestimation
Overestimated This variable indicated whether the SMC stated that the budget impact was overestimated or underestimated. The "not mentioned; no report of the SMC on whether the budget impact was over-or underestimated" was set as the reference case. information about a drug, or new analysis of existing information, the sponsor company may make a resubmission, which is essentially a complete de novo assessment through usual SMC processes. This type of submission is usually after the SMC had already rejected to recommend the product of interest at least once.
Other information
Note: D ¼ 0 was treated as reference category in logistic regression analyses.
ATC, Anatomical Therapeutic Chemical (ATC) Classification System; BC, base case; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; ICER, incremental cost-effectiveness ratio; NICE, National Institute for Health and Care Excellence; QALY, quality-adjusted life-year; SA, sensitivity analysis; SMC, Scottish Medicines Consortium.
* As sorted and presented in "Fortune Global 500 2009 Pharmaceutical Industry" and "Global 
Results
A total of 463 appraisal documents (full submissions and resubmissions) published on the SMC website between January 2006 and July 2013 were reviewed and extracted. Of the 463 submissions, 265 (57%) were accepted for use and 198 (43%) were not recommended for use within NHS Scotland. Of the ones that received a positive opinion, 150 (57%) were accepted for restricted use, e.g. for a limited patient population or for a restricted time period, while 115 submissions were accepted for routine use. Table 2 provides an overview of the results of the univariate analyses including the estimated OR, the probability of positive recommendation, and the number of submissions for each variable and category within a variable. An OR above 1 indicated higher odds of a positive recommendation than rejection. In total, 13 factors demonstrated a significant association with reimbursement recommendation by the SMC (these are marked grey in Table 2 ). Of these, 8 factors were related to clinical evidence, indication and disease characteristics, while 5 factors were associated with the economic evidence and the size of the manufacturer's company.
Base case
Economic evidence seemed to be strongly influential for the reimbursement recommendation. Submissions supported by a cost-minimization analysis had higher odds of receiving positive recommendation (OR=8.3; 95% CI: 3.9 -17.6) than submissions supported by a not robust cost-utility analysis (base case ICER below £30,000/QALY and sensitivity analyses above £30,000/QALY). Similarly, economic evidence showing that the new treatment dominates the comparator treatment (i.e. demonstrating costs savings and yielding additional QALYs) was associated with high odds of a positive recommendation (OR= 6.4; 95% CI: 2.2 -18.9).
Moreover, it was shown that an active controlled trial (OR=2.08; 95% CI: 1.41 -3.07) is preferred over a placebo or an uncontrolled one. A surprising observation was that submissions based on non-superior efficacy results against an active comparator, however, had a significant and higher OR than submissions based on superior efficacy results against active comparator when compared to uncontrolled trials. This is likely explained, however, by insufficient power.
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Implications for Future Reimbursement Submissions
The results of this study present (at least) three important implications for future reimbursement submissions. First, our analyses suggest that the ICER and the uncertainty around the ICER are significant factors for a successful reimbursement submission in the SMC. Consequently, the pricing of the product (including orphandesignated products) should be carefully considered by the manufacturer on the grounds of the implications that the price may have on the reimbursement recommendations of its product [24] .
A cost-minimization analysis assumes similar efficacy and is used to show the difference in cost implications of two or more alternative treatment options [25] . The fact that a performance of cost-minimization analyses was associated with a high probability of positive recommendation suggests that the SMC may prefer a case that can be backed up by a simple pharmacoeconomic analysis, such as a cost-minimization one.
Furthermore, it was shown that the trial design is taken into consideration by the SMC. An active-controlled trial is preferred over the placebo one. Therefore, manufacturers should take this into consideration trying to fulfill the reimbursement requirements along with the marketing authorization needs because this tends to be a hurdle for a product's introduction in the market.
Another interesting insight was drawn from the multivariate analysis, which revealed that an application submitted by one of the big pharmaceutical companies had a higher chance of being accepted for use than did an application submitted by a small company. This is likely explained by the fact that big companies have more experience and fund available for conducting the right trials and for building the economic evidence that is needed for SMC submissions. Hence, appropriate funding for high-quality trials and evidence is a necessary tool along the process of a product's development.
Finally, this research makes the importance or weight of different variables (e.g., clinical, health economic, and burden of illness) on the reimbursement recommendation in Scotland transparent. This is relevant for the understanding of all stakeholders of the Scottish reimbursement process (e.g., SMC, manufacturers, patient interest groups, and clinicians). For manufacturers and lobbying organizations, it could help to further improve their reimbursement submissions and claims regarding their products. Moreover, this transparency can be used, if deemed necessary, for further refinement of the current reimbursement process and criteria. For instance, it is important to mention that patient interest groups have already moved forward into flagging their difficulty in accepting the importance of the ICER to the SMC committee and their concerns about the implications on the access of patients to certain effective medicines [26] . Consequently, SMC is requested to introduce a new, more flexible decision-making framework for the assessment of end-of-life medicines, orphan medicines, and ultraorphan medicines that is not based on cost-effectiveness outcomes [26] . 761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827   828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894 ATC, Anatomical Therapeutic Chemical (ATC) Classification System; BC, base case; BI, budget impact; CI, confidence interval; ICER, incremental cost-effectiveness ratio; SA, sensitivity analysis. * Significant impact has been shown. ATC, Anatomical Therapeutic Chemical (ATC) Classification System; BC, base case; CI, confidence interval; ICER, incremental costeffectiveness ratio; SA, sensitivity analysis; QALY, quality-adjusted life-year. * Examples related to products indicated for nonchronic use: product indicated for treatment of major depressive episodes or for manic episodes associated with bipolar I disorder; Example for ATC N (nervous system) products: product indicated for invasive candidiasis or for topical treatment of moderate scalp psoriasis. Several of the variables that were significant in the univariate analyses were eliminated in the multivariate analyses because the variance they explained was shared with stronger predictive variables. For instance, an orphan product, which was shown to have a significant impact on the univariate analysis, was not an explanatory variable in the multivariate analysis. The reason is that submissions concerning orphan products demonstrated a high ICER; hence, the ICER is a stronger explanatory variable which eventually remains in the analysis.
The area under the ROC curve of the final multivariate model was estimated to be 0.80, indicating that the prediction accuracy of the developed model was reasonably high, i.e. the model was able to predict the SMC decisions correctly in 80% of the cases.
Sensitivity analysis
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¥ Examples related to products indicated for non-chronic use: product indicated for treatment of major depressive episodes or for manic episodes associated with bipolar I disorder; Example for ATC N (nervous system) products: product indicated for invasive candidiasis or for topical treatment of moderate scalp psoriasis.
Conclusions
The purpose of the current study was to investigate the weight the different components of evidence, submitted to the SMC for reimbursement, have on the final recommendation decision.
Out of the 463 submissions that were included in the analyses, 265 were accepted for use (57%), and 198 (43%) were not recommended for use within NHS Scotland. Univariate analyses showed that 13 variables significantly affected the SMC decision. Of those, 7 variables were shown to have meaningful impact in the multivariate analysis. Four of these concerned the outcome of the cost-effectiveness analyses; the fact that a submission was supported by a cost minimization analysis was the strongest positive Other authors have investigated similar research questions but for other countries. For England and Wales, Dakin et al. found that that the most influential factors impacting recommendations were the number of randomized clinical trials, inclusion of cost-utility analysis in submission, the ICER, and whether the product of interest was a life-saving intervention [6] . Devlin et al. also found that the ICER had the most influential impact on the NICE decisions [7] . The results by Cerri et al. indicated that the following factors were important: demonstration of statistical superiority, the ICER, the number of pharmaceuticals appraised within the same appraisal, and the appraisal year [10] . Harris et al. found that for Australia the clinical significance, cost-effectiveness, budget impact and disease severity were the most influential factors for a positive coverage decision [12] . In the Netherlands, Cerri et al. found the following factors to significantly impact the reimbursement decision of the Dutch national health authority: active comparator of the pivotal trial, the budget impact, the therapeutic indication and the target population [11] .
The findings of these studies are difficult to be compared due to differences in reimbursement systems, methodologies applied, and sample of reimbursement cases studied. A common finding in Scotland, England and Wales and Australia, however, was that the ICER is an important criterion for the reimbursement decision [6, 7, 10, 12] , surprisingly not in the Netherlands [11] . Other factors that were of significant impact in our analyses e.g. the size of the company and whether the products are indicated for non-chronic use, were not included and analysed in the other before-mentioned analyses. The therapeutic indication and disease severity were influential in our analyses for Scotland and in the Netherlands and in Australia [11, 12] , but not in England and Wales [6, 7, 10] .
Implications for future reimbursement submissions
The results of this study present (at least) three important implications for future reimbursement submissions. Firstly, our analyses suggest that the ICER and the uncertainty around the ICER are significant factors for a successful reimbursement submission in the SMC. Consequently, the pricing of the product (including orphan designed products) should be carefully considered by the manufacturer on the grounds of the implications that the price may have on the reimbursement recommendations of their product [24] . A cost minimization analysis assumes similar efficacy and is used to show the difference in the costs implications of two or more alternative treatment options [25] . The fact that a performance of cost-minimization analyses was associated with a high probability of positive recommendation suggests that the SMC may prefer a case which can be backed up by a simple pharmacoeconomic analysis, like a cost-minimization one.
Furthermore, it was shown that the trial design is taken into consideration by the SMC. An active-controlled trial is preferred over the placebo one. Therefore, manufacturers should take this into consideration trying to fulfil the reimbursement requirements along with the marketing authorization needs, as this tends to be a hurdle for a product's introduction in the market.
Another interesting insight was drawn from the multivariate analysis, which revealed that an application submitted by one of the big pharmaceutical companies, had a higher chance of being accepted for use than a small company. This is likely explained by the fact that big companies have more experience and fund available for conducting the right trials and for building the economic evidence that is needed for SMC submissions. Hence, appropriate funding for high quality trials and evidence is a necessary tool along the process of a product's development.
Finally, this research makes the importance or weight of different variables (e.g. clinical, health economic, burden of illness) on the reimbursement recommendation in Scotland transparent. This is relevant for the understanding of all stakeholders of the Scottish reimbursement process (e.g. SMC, manufacturers, patient interest groups and clinicians). For manufacturers and lobbying organizations, it could help to further improve their reimbursement submissions and claims regarding their products. Moreover, this transparency can be used if deemed necessary for further refinement of the current reimbursement process and criteria. For instance, it is important to mention that Patient Interest Groups have already moved forward into flagging their difficulty of accepting the importance of the ICER to the SMC committee and their concerns about the implications on the access of patients to certain effective medicines [26] . Consequently, SMC is requested to introduce a new, more flexible decision-making framework for the assessment of end of life medicines, orphan medicines and ultra-orphan medicines that is not based on the cost-effectiveness outcomes [26] . It will be interesting to observe in a future research the consequences of this new approach (when available and implemented) for the assessment process and acceptance rates for these products.
Limitations
Findings of this study should be interpreted with the following limitations. Firstly, no variables related to the decision process (e.g. policy changes, size of the committee, members and expertise) were considered in the analyses. Secondly, the ICER threshold of £30,000/ QALY was used in the analyses, as it is evidently reported in the SMC appraisal decisions as an evidence that is taken into consideration. Yet, the SMC does not have a formal ICER threshold; hence, this value, being the official threshold applied by NICE, was assumed to represent the value upon which a technology is deemed to be cost-effective by the SMC. The arbitrarily chosen thresholds for the ICER (e.g. £30,000/QALY gained) and the budget impact (e.g. £500,000 in year 5) could have affected the results. Furthermore, it should be noted that even though the SMC assessment does not go beyond the company's submission, they might estimate their own unofficial ICER to support their decision. [14, 16] . This analysis, however, was dependent on publicly available information and it was assumed that the published by the SMC base case is the one upon which the final recommendation was based.
Finally, in our study, a positive recommendation was defined as a product being accepted for use with or without any restrictions. For this study, we did not pursue to separate the full acceptance for use from an acceptance for restricted use as the total number of submissions per level of recommendation would have been too low to draw robust conclusions. In addition, it is unknown whether it was the manufacturer's strategic decision to request reimbursement recommendation with restrictions, or it was the SMC who came to this conclusion given the submitted evidence. Therefore, it cannot be assumed that a restricted acceptance represents a lesser favourable decision, as this may serve e.g. the therapeutic indication of the product of interest. Nonetheless, it is acknowledged that future research could take into account the multinomial nature of the recommendation outcome.
The SMC database that was created for this analysis is assessed to be comprehensive, including information from all different components of submitted evidence. In addition, the sample for this analysis is the biggest that has been created for this type of analysis and it's the only one related to the SMC coverage recommendations. Future research could include a consistent assessment of cases and explanatory variables and methodologies across countries, to better understand and explain the differences across different healthcare systems.
To conclude, the current study identified the most influential factors to the reimbursement recommendation by the SMC. It was shown that favourable ICER (i.e. base case ICER and sensitivity analysis around it below £30,000/ QALY gained) is crucial for a successful submission. Both univariate and multivariate analyses showed that this comes in combination with the clinical evidence, the target disease, and the company's size, which also play a significant role in the SMC reimbursement decisions. It is interesting to observe that these conclusions are in line with the publicly stated objective of the SMC: "Will the medicine be effective? Are current treatments better? Does the medicine give value for money compared to existing treatments? These are the main questions asked while considering new medicines' approval" [15] .
